Maura Dougherty

Maura Dougherty

Auto-generated profile, based on publicly available information

Maura Dougherty

VA Health Professions Education Evaluation and Research Fellowship Program, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in JCO Oncology Practice
Verified
Journal Article
Open access
MYMinkyoung Yoo
Minkyoung Yoo
RNRichard E. Nelson
Richard E. Nelson
ZCZachary Cutshall
Zachary Cutshall
MDMaura Dougherty
Maura Dougherty
MKManish Kohli
Manish Kohli
PURPOSE: Several new treatment combinations have been approved in metastatic renal cell carcinoma (mRCC). To determine the optimal therapy on the basis of cost and health outcomes, we performed a cost-effectiveness analysis of approved immunotherapy-tyrosine kinase inhibitor/immunotherapy drug combinations and sunitinib using public payer acquisition costs in the United States. METHODS: We constructed a decision model with a 10-year time horizon. The seven treatment drug strategies included atezolizumab + bevacizumab, avelumab + axitinib, pembrolizumab + axitinib, nivolumab + ipilimumab (NI), nivolumab + cabozantinib, lenvatinib + pembrolizumab, and sunitinib. The effectiveness outcome in our model was quality-adjusted life-years (QALYs) with utility values on the basis of the published literature. Costs included drug acquisition costs and costs for management of grade 3-4 drug-related adverse events. We used a partitioned survival model in which patients with mRCC transitioned between three health states (progression-free, progressive disease, and death) at monthly intervals on the basis of parametric survival function estimated from published survival curves. To determine cost-effectiveness, we constructed incremental cost-effectiveness ratios (ICERs) by dividing the difference in cost by the difference in effectiveness between nondominated treatments. RESULTS: The least expensive treatment was sunitinib ($357,948 US dollars [USD]-$656,100 USD), whereas the most expensive was either lenvatinib + pembrolizumab or pembrolizumab + axitinib ($959,302 USD-$1,403,671 USD). NI yielded the most QALYs (3.6), whereas avelumab + axitinib yielded the least (2.5). NI had an incremental ICER of $297,465 USD-$348,516 USD compared with sunitinib. In sensitivity analyses, this ICER fell below $150,000 USD/QALY if the initial 4-month cost of NI decreased by 22%-38%. CONCLUSION: NI was the most effective combination for mRCC, but at a willingness-to-pay threshold of $150,000 USD/QALY, sunitinib was the most cost-effective approach.

25 November 2020 in ACS Earth and Space Chemistry
Verified
Journal Article
Closed access
NMNathan Miller
Nathan Miller
MDMaura Dougherty
Maura Dougherty
RDRuochen Du
Ruochen Du
TSTyler Sauers
Tyler Sauers
CYCandice Yan
Candice Yan
JMJennifer L. Morford
Jennifer L. Morford

16 June 2023 in F&S Reports
Verified
Journal Article
Open access
JCJoshua C. Combs
Joshua C. Combs
MDMaura Dougherty
Maura Dougherty
MYMeghan U. Yamasaki
Meghan U. Yamasaki
ADAlan H. DeCherney
Alan H. DeCherney
KDKate M. Devine
Kate M. Devine
RNRichard E. Nelson
Richard E. Nelson
To evaluate the cost-effectiveness of in vitro fertilization with preimplantation genetic testing for monogenic disease (IVF + PGT-M) in the conception of a nonsickle cell disease (non-SCD) individual compared with standard of care treatment for a naturally conceived, sickle cell disease (SCD)-affected individual. A Markov simulation model was constructed to evaluate a one-time IVF + PGT-M treatment compared with the lifetime standard of care costs of treatment for an individual potentially born with SCD. Using an annual discount rate of 3% for cost and outcome measures, quality-adjusted life years were constructed from utility weights and life expectancy values and then used as the effectiveness measurement. An incremental cost-effectiveness ratio was calculated for both treatment arms, and a willingness-to-pay threshold of $50,000 per quality-adjusted life year was assumed. Tertiary care or university medical center. A hypothetical cohort of 10,000 patients was analzyed over a lifetime horizon using yearly cycles. In vitro fertilization with preimplantation genetic testing for monogenic disease use in conception of a non-SCD individual. The primary outcomes of interest were the incremental cost and effectiveness of an IVF+PGT-M conception compared with the SOC treatment of an SCD-affected individual. In vitro fertilization with preimplantation genetic testing for monogenic disease was the optimal strategy in 93.17% of the iterations. An incremental savings of $137,594 was demonstrated with a gain of 1.96 QALYs and 3.69 life years over a lifetime. Sensitivity analysis demonstrated that SOC treatment never met equivalent cost-effectiveness. Our model demonstrates that IVF + PGT-M for selection against SCD, compared with lifetime SOC treatment for those affected, is the most cost-effective strategy within the United States healthcare sector.

13 August 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
MDMaura Dougherty
Maura Dougherty
SBSophia M Bartels
Sophia M Bartels
JSJason G Smith
Jason G Smith
SZSteven B Zeliadt
Steven B Zeliadt
JHJusteen Hyde
Justeen Hyde
BKBo Kim
Bo Kim
Introduction Health coaching is the process of working with a trained coach, peer, or healthcare professional towards self-determined health and wellness goals. Health coaching is being increasingly adopted in multiple healthcare settings and has been shown to improve overall health outcomes and long-term maintenance of chronic conditions in multiple countries and healthcare settings. Research surrounding the costs of implementing health coaching and its effects on healthcare costs, particularly long-term costs, has been limited. Although analysis of healthcare costs has become an important priority in recent years, the available literature looking at the cost impacts of health coaching is small and inconclusive, finding mixed results with a variety of methodologies. This scoping review aims to identify gaps in the literature and help set a research agenda regarding the costs of health coaching implementation and its impacts. Methods and analysis The scoping review will be structured according to Levac et al’s enhancement to Arksey and O’Malley’s framework for conducting scoping reviews. PubMed, Embase, and the Health and Medicine Collection will be searched for peer-reviewed research that includes health and wellness coaching and some measurement of cost. Details about the type of study, cost analysis, methodology and results from the included articles will be extracted and summarised. Full-text publications, excluding editorials and opinion pieces, included in this scoping review will be published in 2017 or later, will be written in English, will align with the definition of health coaching as described by the National Board for Health and Wellness Coaching, and will include cost measurement. This review will include publications not captured in the previous integrative literature review looking at the cost-effectiveness of health coaching. Ethics and dissemination Findings will be disseminated through a peer-reviewed publication and through presentations to both health system and community-based entities currently using or considering adopting health coaching. Ethics approval is not a requirement for this review as no human research participants will be involved. All data will be obtained from publicly available literature, with no primary data generated.

20 February 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MKManish Kohli
Manish Kohli
ZCZachary Cutshall
Zachary Cutshall
MDMaura Dougherty
Maura Dougherty
RNRichard Nelson
Richard Nelson
MYMinkyoung Yoo
Minkyoung Yoo
312 Background: Recent FDA approvals for mRCC treatment have resulted in increased effectiveness, drug choices, and costs. We performed a cost effectiveness analysis (CEA) of six recently approved IO-TKI drug combinations and sunitinib. Methods: We used a Markov simulation model from the healthcare sector perspective with a lifetime time horizon. The 7 treatment drug strategies considered in this model included: (1) atezolizumab + bevacizumab (AB), (2) avelumab + axitinib (AA), (3) pembrolizumab + axitinib (PA), (4) nibolumab + ipilimumab(NI), (5) nibolumab + cabozantinib (NC), (6) lenvatinib + pembrolizumab (LP), and (7) sunitinib (S). Input parameters of drug effectiveness and toxicities to construct the model were based on published randomized studies that led to drug approvals. Direct costs for treatment were derived using the VA Federal Supply Schedule (VAFSS). Markov model simulates patient transition between 3 health states at monthly intervals: progression free, progressive disease, and death. The cost-effectiveness outcome in our model were and life-years (LYs), progression-free life-years (PFLYs) gained, and quality-adjusted life-years (QALYs) with utility values based on published literature. Results: The table highlights results of the CEA. The least expensive drug combination was NI ($442,218) while the most expensive was LP ($963,610). AA yielded the most LYs (5.51) and QALYs (5.62) and LP yielded the most PFLYs (1.64) while NL yielded the least LYs (4.35) and PFLYs (1.47) and LP yielded the least QALYs (4.19). AB and S were absolutely dominated strategies yielding less effectiveness and cost more in terms of effectiveness measures. Depending on acceptable willingness-to-pay (WTP) and effectiveness measures, PA or AA were the most cost-effective strategies. Conclusions: Our analyses suggest that based on direct cost acquisition using VA FSS, PA or AA were cost-effective strategies for mRCC with WTP of $20,000 to $200,000 per QALY.

4 August 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
MDMaura Dougherty
Maura Dougherty
SBSophia M Bartels
Sophia M Bartels
JSJason Smith
Jason Smith
SZSteven Zeliadt
Steven Zeliadt
JHJusteen Hyde
Justeen Hyde
BKBo Kim
Bo Kim
Background: Health coaching is the process of using conversation, clinical strategies and interventions to engage clients in setting goals and identifying strategies to facilitate behaviour changes that allow clients to better self-manage their health. Health coaching is a new and growing industry in the USA. With increasing budgetary strain and limited resources, understanding the financial outcomes of adding health coaching is critical. Objectives: The objective of this review was to examine what is known in the literature about health coaching and cost analyses since 2017, building and expanding on the findings of a prior review. This review seeks to identify existing and persisting gaps in the literature and suggest future directions for cost analyses in health coaching interventions. Eligibility criteria: Full-text publications, excluding editorials and opinion pieces, included in this scoping review were published in 2017 or later. Included publications had to be written in English and align with the definition of health coaching described by the National Board for Health and Wellness Coaching. They also had to contain some measurement of cost or cost analysis, indicated by the mention of cost or a related synonym in the methods section. Sources of evidence: PubMed, Embase and the Health Medicine Collection were searched from 1 January 2017 to 7 January 2025 for peer-reviewed research, with an additional search on 5 May 2026 to reflect any additions to the literature since the initial submission. Charting methods: The scoping review was structured according to the enhancement by Levac et al to Arksey and O’Malley’s framework for conducting scoping reviews. Information related to the cost analysis methodology and results was extracted from each of the included articles. Trends across articles were summarised based on key characteristics of the study and the main questions being addressed in the review. Results: Only two studies found statistically significant effects on healthcare costs from health coaching: one found an increase in costs and the other found a decrease. Only one study found health coaching to be cost-effective, with another two studies finding it to be not cost-effective or cost-effective only if the coaching costs less than a certain amount or has an assumed efficacy threshold. Overall, the cost analyses for health coaching lacked transparency in methodology reporting and had a wide variety of methodology and costs included. Synthesis of results was not possible due to inter-study heterogeneity. Conclusion: As there is a move towards standardisation and credentialing of health coaches, there needs to be a similar move towards the standardisation of their cost analyses. This scoping review found mixed, limited evidence regarding the cost outcomes and cost-effectiveness of health coaching. Future research should conduct cost analyses of health coaching interventions according to the structured framework listed in the Consolidated Health Economic Evaluation Reporting Standards, with greater transparency of methods, longer-term results and greater generalisability of results to other geographic locations and health conditions. Cost analysis of health coaching remains an urgent area for standardised and rigorous analysis to better understand the financial implications of adding health coaching to an institution.